BIG

Welcome to the Brand page for “BIG”, which is offered here for The mark consists of the letters b i g with a fanciful curvilinear design above the lettering and, inversely, below the lettering.;house mark for pharmaceutical compositions as prophylaxis, diagnostics or treatments for human and animal disease and illness, infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan disease and drug delivery agents and formulations consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals and other chemical, synthetic or biologic payloads that can be administered in a range of approaches;research and development in the pharmaceutical, biotechnology, and digital medicine fields;.

Its status is currently believed to be active. Its class is unavailable. “BIG” is believed to be currently owned by “PureTech Health LLC”.

Owner:
PURETECH HEALTH LLC
Owner Details
Description:
The mark consists of the letters B I G with a fanciful curvilinear design above the lettering and, inversely, below the lettering.;House mark for pharmaceutical compositions as prophylaxis, diagnostics or treatments for human and animal disease and illness, infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan disease and drug delivery agents and formulations consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals and other chemical, synthetic or biologic payloads that can be administered in a range of approaches;research and development in the pharmaceutical, biotechnology, and digital medicine fields;
Categories: